ERBB2 and breast cancer: The secondary analysis of the ALTTO [114] trials showed that postmenopausal patients with HR-positive HER2-positive BC who were obese at diagnosis and received lapatinib, had a worse prognosis, experienced more grade 3 or 4 adverse events and had higher treatment discontinuation rate [114].